Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination (FLUVAC21)
Efficacy and Safety of a Multistrain Probiotic Formula to Boost the Immune Response to Influenza Virus Vaccination
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18002
- FIBAO- Fundación para la Investigación Biosanitaria de Andalucia Oriental
-
-
Barcelona
-
Granollers, Barcelona, Spain, 08401
- Hospital General de Granollers
-
Sabadell, Barcelona, Spain, 08208
- Hospital Parc Tauli
-
Sant Adrià De Besòs, Barcelona, Spain, 08930
- IDIAP Jordi Gol-Centro de Atención Primaria La Mina
-
Terrassa, Barcelona, Spain, 08221
- Mútua de Terrassa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects 50 - 80 years old receiving seasonal Influenza vaccine in season 2021-2022
- Body mass index (BMI) 18.5-34.9 kg/m2
- Willing to provide informed consent
- Able to follow study procedures, according to the criteria of study investigator
Exclusion Criteria:
- Hypersensitivity to any of the components of influenza vaccine
- Previous influenza infection in the same season (from 01/09/2021)
- Having received influenza vaccination in the previous season less than 9 months before study entry (from 01/01/2021)
- Having received another vaccine -different from COVID19 vaccine- up to 1 month before study inclusion or planning to receive it 1 month after study inclusion
- Active infection at the moment of study entry as diagnosed by study physician
- History of severe allergic reactions (food and non-food), including severe asthma.
- Receiving immunosuppressant therapy, displaying neutropenia, lymphopenia, AIDS, immunoglobulin deficiency, active oncological disease.
- Daily ingestion of any food complement or food added with probiotics (including Actimel o similar products) 2 weeks before inclusion in the study
- Acute pancreatitis, short bowel syndrome or active inflammatory bowel disease
- Diagnosed from other pathologies that according to study physician may compromise the immunological function of the individual (such as immunodeficiencies, lupus, multiple sclerosis, among others)
- Having received antibiotic treatment in the previous month
Exclusion criteria during the study:
- Withdrawal from the study as per study investigator criteria, in case that study procedures are not followed by the participant
- In case of adverse event that prevents them from following study procedures or complying with the treatments under study.
- Failure to comply with study procedures: Complete less than 70% of the days in the patient's diary and/or take less than 80% of the days of the study products.
- Receive any of the unauthorized treatments indicated in the selection criteria, with the exception of antibiotics that will be allowed under medical prescription.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental
Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules.
Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
|
Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
Other Names:
|
|
Placebo Comparator: Placebo
Maltodextrin (E1400, qs) in HPMC capsules
|
One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IgG antibodies against vaccine influenza antigens
Time Frame: 4 weeks (day 1 and day 28)
|
Titer of specific total IgG antibodies against vaccine influenza A and B antigens at day 28
|
4 weeks (day 1 and day 28)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IgG antibodies against vaccine influenza antigens
Time Frame: 8 weeks (day 1 and day 56)
|
Titer of specific total IgG antibodies against vaccine influenza A and B antigens at day 56
|
8 weeks (day 1 and day 56)
|
|
IgM antibodies against vaccine influenza antigens
Time Frame: 8 weeks (day 1 and day 56)
|
Titer of specific total IgM antibodies against vaccine influenza A and B antigens at day 28 and 56
|
8 weeks (day 1 and day 56)
|
|
Seroconversion
Time Frame: 8 weeks (day 1,day 28 and 56)
|
Percentage of patients with seroconversion (defined as 4 fold change in influenza IgG antibodies concentration compared to baseline) at day 28 and 56
|
8 weeks (day 1,day 28 and 56)
|
|
Incidence of influenza like infections (ILI)
Time Frame: 16 weeks (day 1, day 56)
|
Cumulative incidence of influenza like infection (ILI), according to the European Diseases Prevention and Control Center (ECDC) criteria
|
16 weeks (day 1, day 56)
|
|
Incidence of any other respiratory infections (including COVID-19)
Time Frame: 16 weeks (day 1, day 56)
|
Cumulative incidence of any other respiratory infections
|
16 weeks (day 1, day 56)
|
|
Incidence of fever
Time Frame: 16 weeks (day 1, day 56)
|
Cumulative number of days with fever (> 37.5ºC)
|
16 weeks (day 1, day 56)
|
|
Use of analgesics and antibiotics
Time Frame: 16 weeks (day 1, day 56)
|
Cumulative number of days using analgesics and antibiotics
|
16 weeks (day 1, day 56)
|
|
Duration of vaccine-related symptoms: injection-site pain, swelling, redness
Time Frame: 1 week (day 1, day 7)
|
Duration (in days) of symptoms after receiving the flu vaccine.
|
1 week (day 1, day 7)
|
|
Severity of vaccine-related symptoms: injection-site pain, swelling, redness
Time Frame: 1 week (day 1, day 7)
|
Severity of symptoms after receiving the flu vaccine.
Measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe
|
1 week (day 1, day 7)
|
|
Gastrointestinal symptoms
Time Frame: 4 weeks (day 1, day 28)
|
Gastrointestinal manifestations documented through questionnaire in participants diary.
Measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe.
|
4 weeks (day 1, day 28)
|
|
Adverse events
Time Frame: 8 weeks (day 56)
|
Frequency of adverse events reported in medical visits or patient diary
|
8 weeks (day 56)
|
|
Albumin
Time Frame: 4 weeks (day 1, day 28)
|
Albumin concentration in blood
|
4 weeks (day 1, day 28)
|
|
Alkaline phosphatase (ALP)
Time Frame: 4 weeks (day 1, day 28)
|
Alkaline phosphatase (ALP) concentration in blood
|
4 weeks (day 1, day 28)
|
|
Gamma-glutamil transpeptidase (GGT)
Time Frame: 4 weeks (day 1, day 28)
|
Gamma-glutamil transpeptidase (GGT) concentration in blood
|
4 weeks (day 1, day 28)
|
|
Aspartate aminotransferase (GOT)
Time Frame: 4 weeks (day 1, day 28)
|
Aspartate aminotransferase (AST) concentration in blood
|
4 weeks (day 1, day 28)
|
|
Alanine aminotransferase (AST)
Time Frame: 4 weeks (day 1, day 28)
|
Aspartate aminotransferase (AST) concentration in blood
|
4 weeks (day 1, day 28)
|
|
Basic hemogram
Time Frame: 4 weeks (day 1, day 28)
|
Blood cell count
|
4 weeks (day 1, day 28)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines. 2012 Aug;11(8):985-94. doi: 10.1586/erv.12.61.
- Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis. J Infect Dis. 2019 Apr 19;219(10):1525-1535. doi: 10.1093/infdis/jiy720.
- Harper A, Vijayakumar V, Ouwehand AC, Ter Haar J, Obis D, Espadaler J, Binda S, Desiraju S, Day R. Viral Infections, the Microbiome, and Probiotics. Front Cell Infect Microbiol. 2021 Feb 12;10:596166. doi: 10.3389/fcimb.2020.596166. eCollection 2020.
- Trombetta CM, Remarque EJ, Mortier D, Montomoli E. Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses. Influenza Other Respir Viruses. 2018 Nov;12(6):675-686. doi: 10.1111/irv.12591. Epub 2018 Aug 11.
- Lynn DJ, Benson SC, Lynn MA, Pulendran B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat Rev Immunol. 2022 Jan;22(1):33-46. doi: 10.1038/s41577-021-00554-7. Epub 2021 May 17.
- Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - A systematic review. Vaccine. 2018 Jan 4;36(2):207-213. doi: 10.1016/j.vaccine.2017.08.069. Epub 2017 Sep 18.
- Yeh TL, Shih PC, Liu SJ, Lin CH, Liu JM, Lei WT, Lin CY. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018 Jan 25;12:217-230. doi: 10.2147/DDDT.S155110. eCollection 2018.
- Darbandi A, Asadi A, Ghanavati R, Afifirad R, Darb Emamie A, Kakanj M, Talebi M. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20. Int J Infect Dis. 2021 Apr;105:91-104. doi: 10.1016/j.ijid.2021.02.011. Epub 2021 Feb 9. Erratum In: Int J Infect Dis. 2021 Sep;110:337.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AB-FLUVAC21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.